Anaphylaxis Nasal Spray Treatment Approved by MHRA
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the UK’s first needle-free treatment for anaphylaxis. The adrenaline nasal spray offers a new emergency option for people at risk of severe allergic reactions.
Introduction
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved EURneffy, the first adrenaline (epinephrine) nasal spray for the emergency treatment of anaphylaxis in the UK. This marks a major milestone in allergy care, offering a needle-free alternative to traditional auto-injectors or adrenaline ampoules for those experiencing severe allergic reactions.
How the Anaphylaxis Nasal Spray Treatment Works
EURneffy is intended for use in adults and children weighing 30kg (about 66 pounds) or more. It delivers a 2mg dose via the nasal route and has been shown to be effective even when the user has a congested nose. This approval follows a rigorous review through the MHRA’s International Recognition Procedure (IRP), which enables the MHRA to consider the expertise of trusted regulatory partners.
Supporting Easier Access and Use
The product is designed for ease of use and rapid administration in emergencies, particularly beneficial for individuals who are needle-phobic or may struggle to use auto-injectors correctly under pressure
Patients are advised to carry two doses of EURneffy, as a second dose may be required after the first if symptoms persist. Importantly, this nasal spray is not intended to replace adrenaline autoinjectors entirely but rather to provide an additional option in emergency care. Training on proper use is essential, and patients are encouraged to report any side effects via the MHRA Yellow Card scheme.
When will it be available?
With the new treatment expected to come to market towards the end of 2025, this approval represents a significant development in improving accessibility and confidence in anaphylaxis treatment across the UK.
Conclusion
This anaphylaxis nasal spray treatment provides a new alternative to adrenaline auto-injectors. The MHRA continues to support the availability of safe, effective alternatives that improve patient experience and emergency response.
Citation:
Medicines and Healthcare products Regulatory Agency. (2025, 7 August). MHRA approves adrenaline nasal spray: the first needle-free emergency treatment for anaphylaxis in the UK. GOV.UK
Recent Resources
